This pilot double-blind randomized controlled trial assessed the safety and feasibility of administering high-dose intravenous zinc in hospitalized COVID-19 patients. The study involved 33 participants who were randomized to receive either 0.5 mg/kg of elemental zinc (as zinc chloride) or a placebo daily for up to 7 days. The primary
